Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy

BACKGROUND: Endocrine therapy is one of the standard treatments for estrogen-receptor-positive breast cancer patients. Letrozole is the only aromatase inhibitor (AI) included in Thailand’s essential drug list since the change of reimbursement policy in 2008, when patients had to change their AIs (ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Aphinives, Potchavit, Vachirodom, Damnern, Thanapaisal, Chaiyut, Rangsrikajee, Dhanes, Somintara, Ongart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154879/
https://www.ncbi.nlm.nih.gov/pubmed/25249759
http://dx.doi.org/10.2147/BCTT.S67553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154879/
https://www.ncbi.nlm.nih.gov/pubmed/25249759
http://dx.doi.org/10.2147/BCTT.S67553

Ejemplares similares